GalNAc-T6 Inhibitors
GalNAc-T6, a member of the UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase family, plays a crucial role in post-translational modifications by catalyzing the addition of N-acetylgalactosamine to serine or threonine residues of target proteins. This enzymatic process, known as O-glycosylation, is fundamental for the proper function and localization of numerous cellular proteins. GalNAc-T6, specifically, is implicated in various cellular processes such as cell adhesion, signaling, and protein stability regulation.
Inhibition of GalNAc-T6 involves targeting its glycosylation activity, which can be achieved through direct or indirect means. Direct inhibitors interfere with the enzymatic activity of GalNAc-T6, disrupting the glycosylation process and consequently impeding the function of glycosylated proteins. Alternatively, indirect inhibitors modulate cellular signaling pathways or processes involved in glycosylation regulation, thereby down-regulating GalNAc-T6 expression or activity. These mechanisms collectively contribute to the inhibition of GalNAc-T6 and offer avenues for intervention in conditions where aberrant glycosylation is implicated.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alloxan monohydrate | 2244-11-3 | sc-254940 | 10 g | $54.00 | ||
Alloxan disrupts glucose metabolism by inducing oxidative stress, leading to the inhibition of GalNAc-T6 through impaired glycosylation. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose competitively inhibits glucose uptake, disrupting the glycosylation process and subsequently inhibiting GalNAc-T6. | ||||||
STF 31 | 724741-75-7 | sc-364692 | 10 mg | $187.00 | 3 | |
STF-31 targets the Wnt/β-catenin signaling pathway, indirectly inhibiting GalNAc-T6 activity through modulation of downstream effectors. | ||||||
Salicylic acid | 69-72-7 | sc-203374 sc-203374A sc-203374B | 100 g 500 g 1 kg | $47.00 $94.00 $119.00 | 3 | |
Salicylic acid inhibits GalNAc-T6 by interfering with NF-κB signaling, suppressing the expression of genes involved in glycosylation. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin inhibits Hsp90, leading to the degradation of client proteins including GalNAc-T6, thereby suppressing its activity. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin blocks N-glycosylation by inhibiting the transfer of N-acetylglucosamine-1-phosphate, ultimately down-regulating GalNAc-T6. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib targets the c-Abl kinase pathway, indirectly inhibiting GalNAc-T6 through cross-talk between signaling networks. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide inhibits protein synthesis, resulting in the down-regulation of GalNAc-T6 expression and activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits PI3K/Akt signaling, indirectly suppressing GalNAc-T6 activity by disrupting downstream cellular processes. | ||||||
Niclosamide | 50-65-7 | sc-250564 sc-250564A sc-250564B sc-250564C sc-250564D sc-250564E | 100 mg 1 g 10 g 100 g 1 kg 5 kg | $38.00 $79.00 $188.00 $520.00 $1248.00 $5930.00 | 8 | |
Niclosamide inhibits STAT3 signaling, indirectly impairing GalNAc-T6 function through modulation of cytokine-mediated pathways. | ||||||